Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 30;86(11):6619-6635.
doi: 10.1097/MS9.0000000000002611. eCollection 2024 Nov.

Neurological manifestations of lysosomal storage diseases

Affiliations
Review

Neurological manifestations of lysosomal storage diseases

Chukwuka Elendu et al. Ann Med Surg (Lond). .

Abstract

Lysosomal storage diseases (LSDs) encompass a group of rare inherited metabolic disorders characterized by the accumulation of undegraded substrates within lysosomes, leading to multisystemic manifestations, including profound neurological involvement. This article provides a concise overview of the neurological manifestations of LSDs, with a focus on central nervous system (CNS) involvement and treatment strategies. While the paper intricacies of each LSD subtype and its associated CNS manifestations, it aims to provide a summary of the essential findings and implications. The neurological manifestations of LSDs encompass a spectrum of symptoms, including cognitive impairment, motor dysfunction, seizures, and sensory deficits, which significantly impact patients' quality of life and pose therapeutic challenges. Current treatment strategies primarily aim to alleviate symptoms and slow disease progression, with limited success in reversing established neurological damage. Enzyme replacement therapy, substrate reduction therapy, and emerging gene therapies hold promise for addressing CNS involvement in LSDs. However, challenges such as blood-brain barrier penetration and long-term efficacy remain. In addition to discussing treatment modalities, this article highlights the importance of early diagnosis, multidisciplinary care, and patient advocacy in optimizing outcomes for individuals affected by LSDs. Ethical considerations are also addressed, including equitable access to emerging treatments and integrating personalized medicine approaches. Overall, this article underscores the complex interplay between genetics, neuroscience, and clinical care in understanding and managing the neurological manifestations of LSDs while emphasizing the need for continued research and collaboration to advance therapeutic interventions and improve patient outcomes.

Keywords: CNS involvement; lysosomal storage diseases; multidisciplinary care; neurological manifestations; treatment strategies.

PubMed Disclaimer

Conflict of interest statement

The views and opinions expressed in this paper are solely those of the authors and do not necessarily reflect any institution or organization’s official policy or position. The authors declare no conflicts of interest or financial disclosures related to this research.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

References

    1. Giugliani R, Vairo F, Kubaski F, et al. . Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS. Lancet Child Adolesc Health 2018;2:56–68. - PubMed
    1. Sedel F, Turpin JC, Baumann N. Présentations neurologiques des maladies lysosomales chez l’adulte [Neurological presentations of lysosomal diseases in adult patients]. Rev Neurol (Paris) 2007;163:919–929. - PubMed
    1. Pará C, Bose P, Pshezhetsky AV. Neuropathophysiology of lysosomal storage diseases: synaptic dysfunction as a starting point for disease progression. J Clin Med 2020;9:616. - PMC - PubMed
    1. van Gool R, Tucker-Bartley A, Yang E, et al. . Targeting neurological abnormalities in lysosomal storage diseases. Trends Pharmacol Sci 2022;43:495–509. - PubMed
    1. Crawley AC, Walkley SU. Developmental analysis of CNS pathology in the lysosomal storage disease alpha-mannosidosis. J Neuropathol Exp Neurol 2007;66:687–697. - PubMed

LinkOut - more resources